|
Active substance |
Ribociclib |
|
Holder |
Novartis |
|
Status |
Closed |
|
Indication |
In combination with letrozole for adult postmenopausal women as initial endocrine-based therapy for hormone receptor-positive (HR+) HER2-negative (HER2-) locally advanced or metastatic breast cancer. |
|
Documents publics |
|
|
Dernière mise à jour |
17/01/2018 |
Kisqali®
Last updated on 13/09/2024